Evidence map›Paper›PMID 28655899›Full record

ArticleScientific reports2017

Peptides derived from MARCKS block coagulation complex assembly on phosphatidylserine.

Noah Kastelowitz, Ryo Tamura, Abimbola Onasoga, Timothy J Stalker, Ormacinda R White, Peter N Brown, Gary L Brodsky, Lawrence F Brass, Brian R Branchford, Jorge Di Paola and 1 more

Open access · goldAbstract read
In one paragraph

Article in Scientific reports, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
0.7field-weighted citation impact, top 33% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 17 citations in OpenAlex.

  1. Article
  2. Review
  3. Review
  4. Review
  5. Article
  6. Article
  7. MARCKS and Lung Disease.American journal of respiratory cell and molecular biology · 2019
    Review
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 3 institutions in 1 country.

Noah KastelowitzDepartment of Chemistry & Biochemistry and the BioFrontiers Institute, University of Colorado Boulder, Boulder, Colorado, USA.
Ryo TamuraDepartment of Chemistry & Biochemistry and the BioFrontiers Institute, University of Colorado Boulder, Boulder, Colorado, USA.
Abimbola OnasogaDepartment of Pediatrics, University of Colorado School of Medicine, Aurora, Colorado, USA.
Timothy J StalkerDepartment of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, USA.ORCID 0000-0002-0017-4268
Ormacinda R WhiteDepartment of Chemistry & Biochemistry and the BioFrontiers Institute, University of Colorado Boulder, Boulder, Colorado, USA.
Peter N BrownDepartment of Chemistry & Biochemistry and the BioFrontiers Institute, University of Colorado Boulder, Boulder, Colorado, USA.
Gary L BrodskyDepartment of Pediatrics, University of Colorado School of Medicine, Aurora, Colorado, USA.
Lawrence F BrassDepartment of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, USA.
Brian R BranchfordDepartment of Pediatrics, University of Colorado School of Medicine, Aurora, Colorado, USA.ORCID 0000-0002-4076-270X
Jorge Di PaolaDepartment of Pediatrics, University of Colorado School of Medicine, Aurora, Colorado, USA. jorge.dipaola@ucdenver.edu.
Hang YinDepartment of Chemistry & Biochemistry and the BioFrontiers Institute, University of Colorado Boulder, Boulder, Colorado, USA. hubert.yin@colorado.edu.ORCID 0000-0002-9762-4818
University of Colorado Boulder · USUniversity of Colorado Denver · USUniversity of Pennsylvania · US

Funding

Subcellular Mechanisms pf Platelet ActivationP01HL040387 · NHLBI · UNIVERSITY OF PENNSYLVANIA · PI BENNETT, JOEL S. · 1988 to 2018
$35.5M
Thrombosis Models CoreP01HL120846 · NHLBI · UNIVERSITY OF PENNSYLVANIA · PI ABRAMS, CHARLES S. · 2014 to 2018
$12.2M
Microvesicles and exosomes as a cancer biomarker detected with designed peptidesF30CA180249 · NCI · UNIVERSITY OF COLORADO · PI KASTELOWITZ-LIEBERMAN, NOAH · 2013 to 2017
$195k
NCI NIH HHS F30 CA180249NHLBI NIH HHS P01 HL040387NHLBI NIH HHS P01 HL120846
6 · The paper itself

Abstract

Blood coagulation involves activation of platelets and coagulation factors. At the interface of these two processes resides the lipid phosphatidylserine. Activated platelets expose phosphatidylserine on their outer membrane leaflet and activated clotting factors assemble into enzymatically active complexes on the exposed lipid, ultimately leading to the formation of fibrin. Here, we describe how small peptide and peptidomimetic probes derived from the lipid binding domain of the protein myristoylated alanine-rich C-kinase substrate (MARCKS) bind to phosphatidylserine exposed on activated platelets and thereby inhibit fibrin formation. The MARCKS peptides antagonize the binding of factor Xa to phosphatidylserine and inhibit the enzymatic activity of prothrombinase. In whole blood under flow, the MARCKS peptides colocalize with, and inhibit fibrin cross-linking, of adherent platelets. In vivo, we find that the MARCKS peptides circulate to remote injuries and bind to activated platelets in the inner core of developing thrombi.

Indexed as

Blood Coagulation FactorsBlood PlateletsFactor XaFibrinHumansLiposomesMultiprotein ComplexesMyristoylated Alanine-Rich C Kinase SubstratePeptidesPhosphatidylserinesPlatelet ActivationProtein BindingProteolysisSurface Plasmon ResonanceThromboplastinBlood Coagulation FactorsFactor XaFibrinLiposomesMARCKS protein, humanMultiprotein ComplexesMyristoylated Alanine-Rich C Kinase SubstratePeptidesPhosphatidylserinesThromboplastin

Identifiers

PMID28655899
PMCPMC5487340
OpenAlexW2710080611

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.